Publications

5900 Results

A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohort

Authors
Chae YK;Sun R;Patel SP;Giles F;Ohr JP;Worden FP;Suga JM;Naing A;Cohen EE;Wallace J;Kang HS;Fenton S;Chung LY;McLeod CM;Chen HX;Sharon E;Streicher H;Ryan CW;Othus M;Blanke CD;Kurzrock R
Journal / Conference
Ther Adv Med Oncol. 2026 Jul 23;18:17588359261451739. doi: 10.1177/17588359261451739
Year
2026
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
42499790
PMC
PMC13396573
Study Number(s)
S1609

Ovarian Reserve as a Measure of Adjuvant Chemotherapy Benefit in Women with Hormone Receptor Positive (HR+), HER2-negative, Node-positive Breast Cancer in SWOG S1007 (RxPONDER)

Authors
K Kalinsky;W Barlow;R Puri;A Mitra;T Home;J Gralow;K Albain;D Hayes;S Delaloge;N Lin;E Perez;L Goldstein;S Chia;P Rastogi;A Schott;S Shak;D Tripathy;G Hortobagyi;F Meric-Bernstein;P Sharma;L Pusztai;A Thompson;H Pathak;A Godwin
Journal / Conference
Annals of Oncology
Year
2026
Research Committee(s)
Breast
PMID
13488494
PMC
PMC42613139
Study Number(s)
S1007

Adverse Events in a Randomized Trial Comparing Radiation Therapy With or Without Olaparib for Inflammatory Breast Cancer

Authors
R Jagsi;A Meisner;P Chalasani;W Barlow;J Bellon;NL Henry;D Lew;M Matusak;J Moran;L Pierce;E Rakovitch;S Reyes;C Speers;J Unger;J White;W Woodward;R Zellars;L Pusztai;P Sharma
Journal / Conference
Int J Radiat Oncol Biol Phys. 2026 Jul 28:S0360-3016(26)04066-6.
Year
2026
Research Committee(s)
Breast
PMID
42520859
Study Number(s)
S1706

Recurrence Score Gene Group Components and Outcomes in the RxPONDER Trial (SWOG S1007)

Authors
Y Abdou;J Hoag;W Barlow;K Albain;J Gralow;F Meric-Bernstam;D Hayes;N Lin;E Perez;L Goldstein;S Chia;S Dhesy-Thind;P Rastogi;A Schott;J Racz;FL Baehner;D Tripathy;G Hortobagyi;L Pusztai;P Sharma;K Kalinsky
Journal / Conference
J Natl Cancer Inst . 2026 Jul 15:djag221. doi: 10.1093/jnci/djag221
Year
2026
Research Committee(s)
Breast
PMID
42458791
Study Number(s)
S1007

Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner

Authors
A Zadoroznyj;P Eriksson;C Bernardo;?? L Tran;CA Mattsson;T Flaig;C Tangen;S Lerner;D McConkey;M Hoglund;F Leidberg;G Sjodahl
Journal / Conference
NPJ Precision Oncology 2026 Jul 3;10(1):258. doi: 10.1038/s41698-026-01588-7.
Year
2026
Research Committee(s)
Genitourinary
PMID
42399473
PMC
PMC13332042
Study Number(s)
S1314

Federal and Industry Sponsorship in US Cancer Clinical Trials

Authors
Unger JM;Xiao H;LeBlanc M;Hershman DL
Journal / Conference
JAMA Oncology. Published online August 20, 2026. doi:10.1001/jamaoncol.2026.3026
Year
2026
Research Committee(s)
Cancer Care Delivery
PMID
42623089
PMC
PMC13494795

Drug Costs in Federally Sponsored Cancer Clinical Trials: A Systematic Review

Authors
Xiao H;LeBlanc M;Bertagnolli M;Threlkel S;Chansky M;Hershman DL;Unger JM
Journal / Conference
JAMA Netw Open. 2026;9(7):e2625814. doi:10.1001/jamanetworkopen.2026.25814
Year
2026
Research Committee(s)
Cancer Care Delivery
PMID
42518232
PMC
PMC13416910

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

Authors
Lima CMSPR;Yothers G;George TJ;Hochster HS;Sanoff HK;Cohen DJ;Guthrie KA;Jacobs SA;Saeed A;Kopetz S;Colangelo LH;Freeman TJ;Cole SW;Khalil MF;Devanna S;Zuckerman DS;Hong TS;Henry NL;Ganz PA;Blanke CD;Wolmark N;Overman MJ
Journal / Conference
J Clin Oncol. Published online July 29, 2026. doi:10.1200/JCO-25-03052
Year
2026
Research Committee(s)
Symptom Management and Survivorship
PMID
41864782
PMC
PMC13105325

Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826)

Authors
Ahmed S
Journal / Conference
Blood Adv. 2026 Jul 29:bloodadvances.2026021402. doi: 10.1182/bloodadvances.2026021402.
Year
2026
Research Committee(s)
Lymphoma
PMID
42526889
Study Number(s)
S1826

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

Authors
Chen Z;Luan D;Jørgensen RRK;Jakobsen L;Maurer MJ;El-Galaly TC;Nastoupil LJ;Cerhan JR;Flowers CR;Link BK;Lossos IS;Stephens DM;Cohen J;Habermann TM;Nowakowski G;Bartlett N;Friedberg JW;Kahl BS;Leonard JP;Brown P;Smedby KE;Jerkeman M;Martin P
Journal / Conference
Am J Hematol. 2026 Sep;101(9):2137-2146. doi: 10.1002/ajh.70398.
Year
2026
Research Committee(s)
Lymphoma
PMID
42240061
PMC
PMC13428379
Study Number(s)
S1001